1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Lyme disease, caused primarily by the spirochete Borrelia burgdorferi sensu stricto in the United States, is the most commonly reported vector-borne disease with >30,000 confirmed or probable cases reported annually and a recent estimate suggesting that ten-fold more cases may occur. There is currently no human vaccine against B. burgdorferi. However, tick/pathogen control efforts that combine killing of host-seeking ticks with targeting of natural rodent reservoirs for B. burgdorferi can reduce the abundance of host-seeking infected ticks on residential properties. The purpose of the project is to advance knowledge of the impact of protection of single versus multiple adjacent properties - in relation to human landscape use patterns and tick exposure locations – to reduce human exposure to ticks infected with Lyme disease spirochetes.
Funding Opportunity Number: RFA-CK-16-002. Assistance Listing: 93.942. Funding Instrument: CA. Category: HL. Award Amount: $100K – $300K per award.
Get alerted about grants like this
Save a search for “Centers for Disease Control and Prevention - ERA” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Others (see text field entitled Additional Information on Eligibility for clarification). Applicant organizations that request funding above the ceiling amount of the award will not be forwarded to peer review or considered for funding. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $100K – $300K per award Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is February 2, 2016. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
This FOA is to develop, improve, and implement laboratory techniques to assess babies born with severe combined immune deficiency (SCID) and other primary immunodeficiencies using next generation sequencing technologies as a second tier test in state newborn screening aboratories. CDC seeks to evaluate the potential of using next generation sequencing technologies in the state newborn screening laboratory setting. Results of this activity will be used to inform other state newborn screening laboratories about the feasibility of using next generation sequencing technologies in the state newborn screening laboratory setting to evaluate babies that screen positive for SCID and other primary mmunodeficiencies. The ultimate goal is to improve treatment outcomes for babies with SCID or other primary immunodeficiencies. Funding Opportunity Number: RFA-EH-15-002. Assistance Listing: 93.070. Funding Instrument: CA. Category: HL. Award Amount: Up to $350K per award.
The CDC Prevention Epicenters Program has been established to develop, implement and evaluate the effectiveness of epidemiologically-based strategies to improve healthcare quality and patient safety. This funding opportunity announcement is designed to utilize the CDC Prevention Epicenters Program to translate basic, epidemiologic and technologic discoveries into new strategies for improving prevention of HAIs, Antimicrobial resistance (AR) and other adverse events in all types of healthcare facilities in the United States. Funding Opportunity Number: RFA-CK-16-004. Assistance Listing: 93.084. Funding Instrument: CA. Category: HL. Award Amount: $400K – $500K per award.
Arthritis affects 52.5 million adults and is the most common cause of disability in the United States, yet it is relatively understudied given its large burden, especially in the African American population. Osteoarthritis of the hip and knee are the most common causes of arthritis disability. As OA continues to grow in prevalence and burden, much more remains to be learned from a public health perspective about its incidence, prevalence, progression, and the factors associated with each. This need has been described in documents such as the 1999 National Arthritis Action Plan - A Public Health Strategy, and is a priority for the CDC Arthritis Program. The need is also documented in the recommendations of the 2010 National Public Health Agenda for Osteoarthritis.The purpose of this funding opportunity announcement is to support a population-based longitudinal study, which is designed to: (1) refine population-based estimates of the prevalence, incidence, and progression of hip and knee osteoarthritis and related outcomes; (2) gather information on and investigate possible factors (both risk and protective, including other chronic conditions) associated with the above outcomes; and (3) determine racial or ethnic differences in outcomes and in the role of comorbid conditions and the effect of risk factors upon osteoarthritis outcomes. Funding Opportunity Number: RFA-DP-16-003. Assistance Listing: 93.283. Funding Instrument: CA. Category: HL. Award Amount: $600K – $1.5M per award.